Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth Premarin Petition Withdrawn; Firm Hints At Future Action

Executive Summary

Wyeth is reserving its right to file future citizen petitions with regard to the manufacturing of generic Premarin (conjugated estrogens), the company says in a letter formally withdrawing a 1994 petition to block synthetically derived estrogens

You may also be interested in...



Cenestin Settlement: Barr Boosts Branded Business With Five Wyeth Products

Barr will add an oral contraceptive in development at Wyeth as part of an acquisition deal that settles Cenestin antitrust litigation

Cenestin Settlement: Barr Boosts Branded Business With Five Wyeth Products

Barr will add an oral contraceptive in development at Wyeth as part of an acquisition deal that settles Cenestin antitrust litigation

Wyeth Petition To Prevent Generic Premarin: When Is A Horse Not A Horse?

Barr is bracing for Wyeth to renew its citizen petition campaign to block generic Premarin (conjugated estrogens)made from pregnant horses' urine

Related Content

UsernamePublicRestriction

Register

PS040558

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel